Sarcura is developing an instrument platform for the GMP manufacturing of autologous cell therapies. Its platform combines microfluidic processing with silicon chip technology to enable real-time process control and manipulation on a cellular level supporting a fully automated manufacturing system. The company's target is to scale global manufacturing capacity for patient-specific cell therapy cancer treatments from thousands of doses per year to hundreds of thousands.
Select partners: imec.
Select investors IST cube, Nina Capital, Axilium Holding, Austria Wirtschaftsservice Gesellschaft, FFG
Key people 🧑🤝🧑
- Huge market: The global cell therapy market was valued at less than $20 Billion in 2020 and is expected to surpass $45 Billion by 2028, according to Kuick Research. 🔗
- Big opportunity: Cell and gene therapies are poised to revolutionize cancer treatment, though the manufacturing of personalized cell therapies remains a major bottleneck for the industry and leads to very high costs. Sarcura brings processing and real time control to the cellular level in order to fully automate the manufacturing of these highly potent, living medicines.
- Promising tech: Cell therapy transformed cancer treatment, with 85% of patients experiencing complete remission after a cell therapy treatment. 🔗
- Knowledgable founders: Daniela has more than 15 years of big corporate life in the biopharmaceutical sector, Erwin is an experienced innovator with a scientific and industrial background in stem cell biology, while Martin has many years of extensive academic experience in linking science and engineering. 🔗
Sarcura combines an interdisciplinary founders team of accomplished scientists and experienced managers with a research-derived, innovative product for a growing market with a strong need. With this profile, the company fits perfectly into our investment scope of early-stage, science-based start-ups and spin-offs. The team addresses a clear pain point in the market and convinced us with their customer-centric, and technology savvy approach. We are happy to lead this investment round and are looking forward to the next steps together with the founders and fellow investors.
— Florian Resch, Partner at IST cube 🔗
Sarcura addresses the infrastructural need of a growing therapy market to reduce the costs and time of manufacturing cell therapies, in order to bring their life-saving potential to more cancer patients. By applying semiconductor technology embedded in microfluidic processing systems, Sarcura will bring real-time bioprocess control to the cellular level, finally enabling the transformation from industrial biotechnology to personalised medicine.
— Marta-Gaia Zanchi, Ph.D, Partner at Nina Capital 🔗
You have to aim high enough to change something. Sarcura is not an usual 'evolutionary' startup. Instead, they see the big picture ahead of them and know exactly which steps to take to make it a reality.
— Liesbet Lagae, Program Director Life Science Technologies at imec
Last update: August 18, 2022
Disclaimer: We can not guarantee that the information on this page is 100% correct. more